JP2007516966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516966A5 JP2007516966A5 JP2006542741A JP2006542741A JP2007516966A5 JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5 JP 2006542741 A JP2006542741 A JP 2006542741A JP 2006542741 A JP2006542741 A JP 2006542741A JP 2007516966 A5 JP2007516966 A5 JP 2007516966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cancer
- synthetic peptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 110
- 239000003814 drug Substances 0.000 claims 56
- 206010028980 Neoplasm Diseases 0.000 claims 55
- 201000011510 cancer Diseases 0.000 claims 55
- 230000002163 immunogen Effects 0.000 claims 44
- 239000012634 fragment Substances 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 39
- 239000000203 mixture Substances 0.000 claims 39
- 210000002865 immune cell Anatomy 0.000 claims 36
- 229940079593 drug Drugs 0.000 claims 34
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 27
- 208000032839 leukemia Diseases 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 14
- 210000004443 dendritic cell Anatomy 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 206010027406 Mesothelioma Diseases 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 7
- 206010057644 Testis cancer Diseases 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 7
- 201000005202 lung cancer Diseases 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 201000003120 testicular cancer Diseases 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 210000002798 bone marrow cell Anatomy 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 210000002540 macrophage Anatomy 0.000 claims 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102000040856 WT1 Human genes 0.000 claims 4
- 108700020467 WT1 Proteins 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims 3
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 230000008105 immune reaction Effects 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000037029 cross reaction Effects 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000004963 pathophysiological condition Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52595503P | 2003-12-01 | 2003-12-01 | |
| PCT/US2004/040347 WO2005053618A2 (en) | 2003-12-01 | 2004-11-30 | Synthetic hla binding peptide analogues and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007516966A JP2007516966A (ja) | 2007-06-28 |
| JP2007516966A5 true JP2007516966A5 (https=) | 2008-01-17 |
Family
ID=34652399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542741A Pending JP2007516966A (ja) | 2003-12-01 | 2004-11-30 | 合成ｈｌａ結合ペプチド類似体及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7488718B2 (https=) |
| EP (2) | EP1708732B2 (https=) |
| JP (1) | JP2007516966A (https=) |
| AU (1) | AU2004294345B2 (https=) |
| CA (1) | CA2548135C (https=) |
| ES (1) | ES2402184T5 (https=) |
| WO (1) | WO2005053618A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060127409A1 (en) * | 2003-12-01 | 2006-06-15 | Scheinberg David A | Bcr-abl vaccines and methods of use thereof |
| CA2548135C (en) * | 2003-12-01 | 2014-04-22 | Sloan-Kettering Institute For Cancer Research | Synthetic hla binding peptide analogues and uses thereof |
| US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
| EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| WO2007120673A2 (en) * | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| CA2663954A1 (en) * | 2006-09-19 | 2008-04-24 | Human Biomolecular Research Institute | Curcumin analogs, diagnostic methods and genetic markers for diagnosing and treating alzheimer's disease |
| BRPI0808084A2 (pt) * | 2007-02-27 | 2014-07-22 | Int Inst Cancer Immunology Inc | Método para ativação de células t auxiliadoras e composição para uso no método. |
| EP2216041A4 (en) * | 2007-11-20 | 2012-10-24 | Nec Corp | METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR |
| CA2940962C (en) * | 2007-12-05 | 2018-07-24 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
| WO2009137872A1 (en) * | 2008-05-14 | 2009-11-19 | Simons Haplomics Limited | Methods and compositions for the treatment of cancer |
| CA2809362C (en) * | 2010-08-24 | 2020-03-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| EP2738253A4 (en) | 2011-07-29 | 2015-04-22 | Riken | CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID |
| US9539299B2 (en) * | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| RS61173B1 (sr) * | 2013-01-15 | 2021-01-29 | Memorial Sloan Kettering Cancer Center | Imunogeni wt-1 peptidi i postupci za njihovu upotrebu |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| SMT202200370T1 (it) | 2015-11-20 | 2022-11-18 | Memorial Sloan Kettering Cancer Center | Composizione per il trattamento del cancro |
| WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
| WO2018039205A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
| US12383608B2 (en) | 2016-11-30 | 2025-08-12 | Sumitomo Pharma Co., Ltd. | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| JPWO2018181648A1 (ja) | 2017-03-30 | 2020-02-13 | 大日本住友製薬株式会社 | Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| EP3700575A1 (en) | 2017-10-24 | 2020-09-02 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| JP7162675B2 (ja) | 2018-09-28 | 2022-10-28 | 住友ファーマ株式会社 | 注射用組成物 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| JP7153287B2 (ja) * | 2020-05-12 | 2022-10-14 | 住友ファーマ株式会社 | 癌を処置するための医薬組成物 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| MX2024001843A (es) | 2021-08-12 | 2024-05-16 | Int Inst Cancer Immunology Inc | Composición farmacéutica y método para tratar o prevenir cáncer. |
| CN114149970B (zh) * | 2021-11-09 | 2024-06-18 | 因诺伟(北京)生物医疗科技有限公司 | 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| CA2401070A1 (en) * | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| CA2548135C (en) * | 2003-12-01 | 2014-04-22 | Sloan-Kettering Institute For Cancer Research | Synthetic hla binding peptide analogues and uses thereof |
-
2004
- 2004-11-30 CA CA2548135A patent/CA2548135C/en not_active Expired - Lifetime
- 2004-11-30 AU AU2004294345A patent/AU2004294345B2/en not_active Expired
- 2004-11-30 US US10/999,425 patent/US7488718B2/en not_active Expired - Lifetime
- 2004-11-30 ES ES04812790.6T patent/ES2402184T5/es not_active Expired - Lifetime
- 2004-11-30 EP EP04812790.6A patent/EP1708732B2/en not_active Expired - Lifetime
- 2004-11-30 JP JP2006542741A patent/JP2007516966A/ja active Pending
- 2004-11-30 EP EP11189059A patent/EP2478913A1/en not_active Withdrawn
- 2004-11-30 WO PCT/US2004/040347 patent/WO2005053618A2/en not_active Ceased
-
2005
- 2005-09-12 US US11/223,139 patent/US7598221B2/en active Active
-
2009
- 2009-10-06 US US12/574,555 patent/US20100239547A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007516966A5 (https=) | ||
| JP4480580B2 (ja) | Ｗｔ１置換型ペプチド | |
| EP2385117B1 (en) | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same | |
| DK2547364T3 (en) | Peptides, conjugates and methods for increasing the immunogenicity of a vaccine | |
| JP6367950B2 (ja) | 前立腺癌治療用組成物 | |
| JP6266811B2 (ja) | 血管新生病の免疫療法 | |
| RU2714117C2 (ru) | Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток | |
| TWI353250B (en) | Glp-1 pharmaceutical compositions | |
| TWI455721B (zh) | 癌疫苗組合物 | |
| WO2005095598A1 (ja) | Ｗｔ１由来の癌抗原ペプチド | |
| EP3094652A1 (en) | Novel vaccines against hpv and hpv-related diseases | |
| JP2000502327A (ja) | ジフテリア毒素のエピトープ | |
| BRPI0708737A2 (pt) | mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural | |
| CN111565746A (zh) | 用于预防和治疗多种黄病毒的mhc i类相关肽 | |
| CN109718363B (zh) | 预防、缓解或治疗阿尔茨海默病的肽及其应用 | |
| JP2022513209A (ja) | オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物 | |
| CN101072875B (zh) | 新型癌抗原肽及其用途 | |
| US11033609B2 (en) | Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis | |
| WO2015148831A1 (en) | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| JP2001514659A (ja) | ドラスタチン−１５誘導体とタキサンとの併用 | |
| JP2002538166A (ja) | Ｍｈｃクラスｉｉによって提示されるｍａｇｅ−３由来免疫原性ペプチドおよびその使用 | |
| CN114129711B (zh) | 度拉糖肽在制备抗肿瘤药物中的应用 | |
| WO2016097753A1 (en) | Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis | |
| US11712466B2 (en) | Vaccine composition |